Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PR-negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00559507
What this trial is testing

Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery

Who this might be right for
Estrogen Receptor-negative Breast CancerMale Breast CancerProgesterone Receptor-negative Breast Cancer+4 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Ended earlyNCT02624700
What this trial is testing

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast CancerRecurrent Breast Cancer
Virginia Commonwealth University 13
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Very early researchActive Not RecruitingNCT02744053
What this trial is testing

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+1 more
M.D. Anderson Cancer Center 96
Testing effectiveness (Phase 2)Study completedNCT02418481
What this trial is testing

Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)

Who this might be right for
Breast Cancer
Fuda Cancer Hospital, Guangzhou 40
Large-scale testing (Phase 3)Study completedNCT01881230
What this trial is testing

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

Who this might be right for
Breast TumorBreast CancerCancer of the Breast+8 more
Celgene 191
Not applicableStudy completedNCT03981705
What this trial is testing

Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

Who this might be right for
TN ER-/PR-/HER2- Breast CancerTriple Negative Breast CancerHER2-positive Breast Cancer+1 more
Masonic Cancer Center, University of Minnesota 8
Testing effectiveness (Phase 2)Study completedNCT01818063
What this trial is testing

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+5 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 9
Testing effectiveness (Phase 2)WithdrawnNCT03872505
What this trial is testing

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Cedars-Sinai Medical Center
Large-scale testing (Phase 3)Active Not RecruitingNCT01349322
What this trial is testing

Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Who this might be right for
Breast Cancer
Radiation Therapy Oncology Group 2,354
Testing effectiveness (Phase 2)Study completedNCT02260531
What this trial is testing

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Who this might be right for
Breast CancerBrain Tumor - Metastatic
Dana-Farber Cancer Institute 36
Not applicableStudy completedNCT02654431
What this trial is testing

Identification and Semi -Quantification of ER/PR Proteins Expression

Who this might be right for
Breast Cancer
Applied Spectral Imaging Ltd. 350
Testing effectiveness (Phase 2)Study completedNCT01677455
What this trial is testing

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Who this might be right for
Breast CancerHER-2 Positive Breast CancerTriple Negative Breast Cancer+1 more
Synta Pharmaceuticals Corp. 51
Testing effectiveness (Phase 2)Study completedNCT03691493
What this trial is testing

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+4 more
Emory University 36
Testing effectiveness (Phase 2)Study completedNCT05159778
What this trial is testing

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Who this might be right for
Malignant Neoplasm of Breast
HiberCell, Inc. 26
Large-scale testing (Phase 3)Study completedNCT01958021
What this trial is testing

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Novartis Pharmaceuticals 668
Large-scale testing (Phase 3)WithdrawnNCT03081234
What this trial is testing

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)WithdrawnNCT06938711
What this trial is testing

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc.
Large-scale testing (Phase 3)Study completedNCT02926196
What this trial is testing

Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

Who this might be right for
Triple Negative Breast Neoplasms
Istituto Oncologico Veneto IRCCS 474
Testing effectiveness (Phase 2)Study completedNCT01151046
What this trial is testing

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Who this might be right for
Her2 Negative Breast Cancer Patients
Merrimack Pharmaceuticals 118
Next Page